[PAF receptor antagonist in asthma therapy]

¹Department of Medicine and Clinical Immunology, Dokkyo University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|November 1, 1996

Summary

Platelet-activating factor (PAF) is a key mediator in asthma, causing symptoms like bronchoconstriction. Current asthma drugs can suppress these PAF-induced responses, informing the development of new treatments.

Area of Science:

Immunology
Pharmacology
Respiratory Medicine

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis.

Allergy·2023

A possible animal model for critical colonisation.

Journal of wound care·2010

Salmonella enterica serovar Typhi in Japan, 2001-2006: emergence of high-level fluoroquinolone-resistant strains.

Epidemiology and infection·2009

FcepsilonRI-mediated thymic stromal lymphopoietin production by interleukin-4-primed human mast cells.

The European respiratory journal·2009

Increased fat:carbohydrate oxidation ratio in Il1ra (-/-) mice on a high-fat diet is associated with increased sympathetic tone.

Diabetologia·2008

Transforming growth factor-beta(2) polymorphisms are associated with childhood atopic asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2007

See all related articles

Related Experiment Videos

[PAF receptor antagonist in asthma therapy]

Area of Science:

Related Concept Videos

Related Articles